Gunning for first chikungunya vaccine OK, Valneva raids GSK for a seasoned commercial chief
Valneva may be downsizing in the wake of its Covid-19 setback, but it’s also adding expertise where it needs.
The French vaccine maker has appointed Dipal Patel as chief commercial officer, a new position it recently created as it gears up for market entry of its chikungunya vaccine candidate. In Patel, Valneva nabs an 18-year GSK veteran who’s managed commercial operations in multiple countries. Most recently, she was the global lead for Shingrix, GSK’s shingles vaccine.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.